American Gene Technologies®

In The News

Try these: Jeff GalvinHIVAmerican Gene TechnologiesPhenylketonuria

AGT Spins Out Addimmune, Focusing on Functional HIV Cure

Jul 19, 2023

Original Post on Genengnews By: Alex Philippidis According to CEO Jeff Galvin, the cell and gene therapy developer hopes its Addimmune spinout will pick up where AGT leaves off in developing a one-time treatment for HIV, in light of positive early data.   A leading…

Read More

American Gene Technologies Spinoff Sets Sights on Advancing Cell Therapy for HIV

Jul 13, 2023

Original Post on Precision Medicine Online By: Jessica Kim Cohen   NEW YORK – American Gene Technologies (AGT), a 15-year-old privately held biotech firm, is spinning off its HIV drug development program into a separate company that will exclusively focus on advancing therapeutics against the AIDS-causing virus. The…

Read More

CityBiz: Interview with Jeff Galvin, CEO & Founder of American Gene Technologies and Addimmune

Jul 11, 2023

Original Post on Citybiz  By Edwin Warfield Jeff Galvin is the CEO and Founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety…

Read More

Raif Derrazi Interviews Jeff Galvin on HIV Clinical Trial Updates & Addimmune

Jun 30, 2023

CEO Jeff Galvin joins HIV activist and Youtube creator Raif Derrazi to discuss the launch of Addimmune™ – a new HIV-focused spinoff company that will focus solely on advancing an HIV cure, building upon more than a decade of work by American Gene Technologies® (AGT™). Galvin provides insights on data…

Read More

The Bay Area Reporter: Endowment Honors Pioneering HIV Doctor, Dr. Conant

Jun 22, 2023

Original Post in The Bay Area Reporter  By: Matthew S. Bajko   A new endowment named in honor of the pioneering HIV physician Dr. Marcus Conant aims to help educate future generations of health care providers interested in caring for people living with HIV and…

Read More

ShareTreck: Jeff Galvin Weighs in on Addimmune’s Launch and AGT103-T Updates

Jun 22, 2023

American Gene Technologies® CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to share updates on AGT103-T, as well as the launch of the new HIV-focused spinoff company – Addimmune. Following a successful Phase 1 clinical trial, Addimmune will build AGT’s success,…

Read More

NBC4: Rockville Biotech Shares Encouraging News in HIV Fight

Jun 21, 2023

CEO Jeff Galvin joins NBC 4 to discuss the success of AGT’s Phase 1 HIV gene and cell therapy clinical trial, as well as plans to advance to Phase 2 through Addimmune™ – a new spinoff company harnessing gene and cell therapy technologies for a…

Read More

DC News Now: Company Launches New Company “Addimmune” to Focus Exclusively on Developing Cure for HIV

Jun 20, 2023

Original Post in DC News Now. By: Shennekia Grimshaw American Gene Technologies (AGT™), a clinical-stage biotechnology company based in Rockville, Maryland, is launching a new company – Addimmune – to continue to develop gene and cell therapy technologies to cure HIV.    Addimmune will focus…

Read More

WTOP: Rockville Gene Therapy Company Takes Next Step Toward HIV Cure

Jun 19, 2023

Original Post in WTOP By: Jeff Clabaugh There are treatments to keep HIV patients healthy and the virus at bay, but there is still no known cure. A Rockville, Maryland, company thinks it’s headed in the right direction.   American Gene Technologies, a 15-year-old gene…

Read More

BioWorld: Addimmune Launches to Create a Functional Cure for HIV

Jun 18, 2023

Original Post in BioWorld. By: Lee Landenberger For Jeff Galvin, the CEO and founder of newly launched Addimmune, HIV is not a condition that’s in the rearview mirror. It needs a functional cure to save lives, make people healthier and save money that need not have…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. #celltherapy #biotech ... See MoreSee Less
View on Facebook
M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest. ... See MoreSee Less
View on Facebook
AGT CEO, Jeff Galvin, had a chat with social media influencer and HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Dive into the conversation as they shed light on the research and what lies ahead in our mission to find a cure for HIV! #hivcure #HIVresearch #clinicaltrials ... See MoreSee Less
View on Facebook
Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. #science #healthcare ... See MoreSee Less
View on Facebook